Adicet Bio (ACET)
(Real Time Quote from BATS)
$1.25 USD
+0.02 (1.63%)
Updated Jul 16, 2024 11:10 AM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ACET 1.25 +0.02(1.63%)
Will ACET be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ACET based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ACET
Adicet (ACET) Up as Kidney Cancer Drug Gets FDA's Fast Track Tag
Why Adicet Bio (ACET) Stock Might be a Great Pick
ACET: What are Zacks experts saying now?
Zacks Private Portfolio Services
Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data
Is Adicet Bio (ACET) Outperforming Other Medical Stocks This Year?
Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why
Other News for ACET
Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Buy Rating for Adicet Bio: Promising Outlook with Innovative CAR T Cell Therapy and Strong Financial Projections
FDA clears IND application for Adicet Bio’s CAR T cell therapy candidate
Adicet Bio Advances with FDA Clearance and Upcoming Trial